Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 2, 2002 - Issue 3
Submit an article Journal homepage
15
Views
5
CrossRef citations to date
0
Altmetric
Review

Determinants of costs in blood services: blood transfusion from an economic perspective

Arturo Pereira Service of Hemotherapy and Hemostasis and Blood Bank, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. [email protected]
Pages 201-210 | Published online: 09 Jan 2014

References

  • Jefferies LC, Sachais BS, Young DS. Blood transfusion costs by diagnosis-related groups in 60 university hospitals in 1995. Transfusion 41(4), 522–529 (2001).
  • •Blood services account for 1% of all hospital costs, both for medical and surgical DRGs.
  • Wallace EL. Costing blood products and services. Transfusion 31(4), 293–295 (1991).
  • Guest JF, Munro V, Cookson RE The annual cost of blood transfusion in the United Kindom. Clin. Lab. Haem. 20(2), 111–118 (1998).
  • ••One of the few published studies dealingwith the economics of blood services at a national level.
  • Tretiak R, Laupacis A, Riviere M, McKerracher K, Souetre E. Cost of allogeneic and autologous blood transfusion in Canada. Can. Med. Assoc. J. 154(10), 1501–1508 (1996).
  • •In Canada, delivery of blood to patients (handling of blood, including laboratory testing, from arrival to the hospital to its administration to patients) is the most costly item of blood services, followed by collection from donors.
  • Cantor SB, Hudson DV, Lichtiger B, Rubenstein EB. Cost of blood transfusion: a process-flow analysis. J. Clin. Oncol. 16(10), 2364–3370 (1998).
  • Crémieux PY, Barrett B, Anderson K, Slavin MB. Cost of out-patient blood transfusion in cancer patients. J. Clin. Oncol. 18(14), 2755–2761 (2000).
  • Titmuss RM. The gift relationship: from human blood to social policy The New Press, New York, USA (1997).
  • ••Re-edition of the classic book in whichRichard Titmus compared the UK and US blood transfusion services in the 1960s to conclude that the latter was less safe and less efficient because it was based on paid donations.
  • Despotis GJ, Goodnough LT, Dynis M, Baorto D, Spitznagel E. Adverse effects in platelet apheresis donors: a multivariate analysis in a hospital-based program. Vox Sang. 77(1), 24–32 (1999).
  • Cable RG, Edwards RL. The use of platelet concentrates venusplateletpheresis — the donor perspective. 7iansfusion41(6), 727–729 (2001).
  • Goodnough LT, Ali S, Despotis G, Dynis M, DiPersio JE Economic impact of donor platelet count and platelet yield in apheresis products: relevance for emerging issues in platelet transfusion therapy. Vox Sang 76(1), 43–49 (1999).
  • Strauss RG. Economy of platelet transfusion from a hospital perspective:pricing predicates practice. Transfusion 41(12), 1617–1624 (2001).
  • ••The author shows how pricing of bloodproducts may influence on practice and to which extent the interest of blood-banks may differ from that of hospitals and patients.
  • Ackerman SJ, Klumpp TR, Guzman GI et al Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion 40(12), 1457–1462 (2000).
  • •Shows that efforts to decrease blood-bank costs by transfusing split, lower-dose apheresis platelet units results in a disproportionate increase in the number of transfusions per patient, with a corresponding increase in overall hospital transfusion costs.
  • Chiavetta JA, Ennis M, Gula CA, Baker AD, Chambers TL. Test-seeking as motivation in volunteer blood donors. Thansfus. Med. Rev 14(3), 205–215 (2000).
  • Stigum H, Bosnes V, Magnus P, ajasaeter H. Risk behaviour among blood donors who give blood in order to be tested for the human immunodeficiency virus. Vox Sang 80(1), 24–27 (2001).
  • Starr D. Blood: an epic history of medicine and commerce Alfred A Knopf, Inc., New York, USA (1998). Very readable history of blood transfusion, showing how perverse incentives may lead to the wrong decisions.
  • Steffen M. The nation's blood: medicine, justice and the state in France. In: Blood feuds: AIDS, blood and the politics of medical disaster: Feldman EA, Bayer R (Eds), Oxford University Press, New York, USA, 96–126 (1999).
  • Vamvalcas EC. Epidemiology of blood transfusion and forecast of the demand of blood. In: Evidence-based practice of transfusion medicine. Vamvakas EC (Ed.), AABB Press, Bethesda, USA, 177–99 (2001).
  • Sanchez AM, Ameti DI, Schreiber GB et al The potential impact of incentives on future blood donation behavior. Transfusion 41(2), 172–178 (2001).
  • Jeffrey G, Adams PC. Blood from patients with hemochromatosis - a wasted resource? 7iansfusion 39(6), 549–550 (1999).
  • Sacher RA. Hemochromatosis and blood donors: a perspective. 7iansfusion 39(6), 551–554 (1999).
  • Tomasulo P. An outrageous alternative to voluntarism. Transfus. Med. 9(4), 359–363 (1999).
  • •Some 'outrageous', but not irrational reflections on the pros and cons of volunteer blood donation.
  • Strauss RG. Blood donations, safety and incentives. Transfusion 41(2), 165–167 (2001). Very good and brave editorial on volunteer versus remunerated blood donation.
  • Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA. Risk of human immunodeficiency virus (HIV) transmission by blood transfusion before implementation of HIV-1 antibody testing. The transfusion Safety Study Group. 7iansfusion31(1), 4–11 (1991).
  • Ban-era JM, Bruguera M, Ercilla MG et al Incidence of non-A, non-B hepatitis after screening blood donors for antibodies to hepatitis C virus and surrogate markers. Ann. Intern. Med 115(8), 596–600 (1991).
  • Pereira A, Sanz C. A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. 7iansfusion 40(10), 1182–1191 (2000).
  • AuBuchon J. Blood transfusion options: improving outcomes and reducing costs. Arch. Pathol Lab. Med. 121(1), 40–47 (1996).
  • •Review of methods that may be of use in increasing quality and productivity in blood services.
  • Pietersz RN, de Korte D, Reesink HW, Dekker WJ, van den Ende A, Loos JA. Storage of whole blood up to 24 hat ambient temperature prior to component preparation. Vox Sang: 56 (3), 145–150 (1989).
  • Pietersz RN, Reesink HW, Dekker WJ, Fijen FJ. Preparation of leukocyte-poor platelet concentrates from buffy coats. I. Special inserts for centrifuge cups. Vox Sang. 53(4), 203–207 (1987).
  • Hogman CF, Eriksson L, Hedlund K, Wallvik J. The bottom and top system: a new technique for blood component preparation and storage. Vox Sang. 55(4), 211–217 (1988).
  • Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl. J. Med. 339(6), 380–386 (1998).
  • Graham JD, Corso PS, Morris JM, Segui- Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Ann. Rev Public. Health 19,12
  • AuBuchon JP, Kruskall MS. Transfusion safety: realigning efforts with risks. Transfusion37 (11-12), 1211–1216 (1997).
  • ••The authors made a strong case forrealigning financial efforts with actual risks in the implementation of new safety technologies.
  • AuBuchon JP. Optimizing the cost- effectiveness of quality assurance in transfusion medicine. Arch. Pathol Lab. Med. 123(7), 603–606 (1999)
  • AuBuchon JR Cost-effectiveness of new blood safety technologies. Dev. Biol. Stand. 102,211–215 (2000).
  • •Recent review of the cost-effectiveness of new safety measures in blood services.
  • Pereira A. Cost-effectiveness analysis and the selection of blood products. CI.117: Opin. Hematol 7(6), 420–425 (2000).
  • •Another recent review of the cost-effectiveness of new safety measures in blood services.
  • Canadian Co-ordinating Office for Health Technology Assessment: Leukoreduction: The techniques Used, Their Effectiveness and Costs. Canadian Co-ordinating Office for Health Technology Assessment (CCOHTA) Ottawa, Canada (1998).
  • Dzik S, AuBuchon JP, Jeffries L et al Leukocyte reduction of blood components: public policy and new technology. Tmnsfus. Med. Rev 14(1), 34–52 (2000).
  • Ruiz MS, Gable AR, Kaplan EH, Stoto MA, Fineberg H, Trussell J. Institute of Medicine. No time to lose —getting more from HIV prevention. National Academy Press, Washington, DC, USA (2000).
  • Echatson J, Petz L, Keeler E et al The cost- effectiveness of preoperative autologous blood donation. N. Engl. Med 332(11), 719–724 (1995).
  • Jackson BR, Umlas J, AuBuchon JP. The cost-effectiveness of postoperative recovery of RBCs in preventing transfusion-associated virus transmission after joint arthroplasty. 7iansfusion 40(9), 1063–1066 (2000).
  • Barosi G, Marchetti M, Liberato NL. Cost- effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. BE J. Cancer78(6), 781–787 (1998).
  • Coyle D, Lee KM, Ferguson DA et al Economic analysis of erythropoietin use in orthopedic surgery. Tmnsfus. Med. 9(1), 21–30 (1999).
  • Lopez-Plaza I, Weissfeld J, Triulzi FL. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 39 (9), 925–932 (1999).
  • Jackson BR, AuBuchon JP, Birkmeyer JL. Update of cost-effectiveness analysis forsolvent-detergent-treated plasma. JAMA 282(4), 329 (1999).
  • Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of stardardplasma. Transfusion 39(5), 479–487 (1999).
  • Busch MP, Dodd RY, Lackritz EM, AuBuchon JP, Birkmeyer JD, Petersen LR. Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus Type 1 infections. The HIV Blood Donor Study Group. 7iansfusion 37(10), 1003–1011 (1997).
  • AuBuchon JP, Birkmeyer JD, Busch MP Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 37(1), 45–51(1997).

Websites

  • Statline — Washington News Briefs, July 18, 2001 (www.cbbsweb.org/capSTATulr.htm)
  • Response to the American Hospital Association (www.redcross.org/services-biomedlbloodlsypply/072701.html)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.